Tech Company Financing Transactions
Gilgamesh Pharmaceuticals Funding Round
On 3/24/2026, Gilgamesh Pharmaceuticals announced $60 million in Series A financing from Satori Capital and Prime Movers Lab.
Transaction Overview
Company Name
Announced On
3/24/2026
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors
Satori Capital (Lead Investor) (Amy Kruse)
Proceeds Purpose
Proceeds from this additional financing will support the advancement of Gilgamesh Pharma's portfolio of novel neuropsychiatric therapeutics, all of which are novel chemical entities (NCEs) with composition of matter IP, as well as the continued expansion of the company's discovery platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
113 University Pl. 1019
New York, NY 10003
USA
New York, NY 10003
USA
Phone
Undisclosed
Email Address
Overview
Gilgamesh is a serious mental health science focused, preclinical biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCE's) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jonathan Sporn
Chief Scientific Officer
Dalibor Sames
Co-Founder
Michael Cunningham
Co-Founder
Andrew Kruegel
Co-Founder
Jeffrey Witkin
VP - Operations
Kevin Murphy
Browse more venture capital transactions:
Prev: 3/24/2026: EpiFrontier Therapeutics venture capital transaction
Next: 3/24/2026: Dash0 venture capital transaction
Share this article
About Database of VC Transactions
We report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs